Ionis Pharmaceuticals Inc (IONS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ionis Pharmaceuticals Inc (IONS) has a cash flow conversion efficiency ratio of 1.288x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($565.53 Million) by net assets ($439.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ionis Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Ionis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Ionis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ionis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ionis Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Ionis Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Henry Schein Inc
NASDAQ:HSIC
|
-0.020x |
|
Meridian Energy Ltd
AU:MEZ
|
0.038x |
|
Riot Platforms, Inc.
NASDAQ:RIOT
|
-0.041x |
|
Wisetech Global Ltd
AU:WTC
|
0.072x |
|
Suzhou Maxwell Technologies Co Ltd Class A
SHE:300751
|
0.005x |
|
Glaukos Corp
NYSE:GKOS
|
-0.019x |
|
Ternium SA ADR
NYSE:TX
|
0.013x |
|
Yes Bank Limited
NSE:YESBANK
|
0.233x |
Annual Cash Flow Conversion Efficiency for Ionis Pharmaceuticals Inc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Ionis Pharmaceuticals Inc from 1991 to 2025. View Ionis Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $489.09 Million | $-268.58 Million | -0.549x | +35.50% |
| 2024-12-31 | $588.35 Million | $-500.95 Million | -0.851x | -7.07% |
| 2023-12-31 | $386.69 Million | $-307.51 Million | -0.795x | -66.05% |
| 2022-12-31 | $572.89 Million | $-274.37 Million | -0.479x | -1300.46% |
| 2021-12-31 | $772.00 Million | $30.80 Million | 0.040x | -6.30% |
| 2020-12-31 | $843.00 Million | $35.89 Million | 0.043x | -79.25% |
| 2019-12-31 | $1.69 Billion | $345.72 Million | 0.205x | -59.60% |
| 2018-12-31 | $1.19 Billion | $602.89 Million | 0.508x | +22.10% |
| 2017-12-31 | $418.72 Million | $174.15 Million | 0.416x | +136.94% |
| 2016-12-31 | $99.56 Million | $-112.11 Million | -1.126x | -1170.20% |
| 2015-12-31 | $200.79 Million | $21.12 Million | 0.105x | +331.52% |
| 2014-12-31 | $257.78 Million | $6.29 Million | 0.024x | -85.47% |
| 2013-12-31 | $378.39 Million | $63.49 Million | 0.168x | +1534.74% |
| 2012-12-31 | $182.77 Million | $1.88 Million | 0.010x | +101.53% |
| 2011-12-31 | $171.43 Million | $-114.80 Million | -0.670x | -157.51% |
| 2010-12-31 | $244.54 Million | $-63.59 Million | -0.260x | +27.56% |
| 2009-12-31 | $302.06 Million | $-108.44 Million | -0.359x | -117.65% |
| 2008-12-31 | $104.25 Million | $212.03 Million | 2.034x | -42.28% |
| 2007-12-31 | $10.24 Million | $36.09 Million | 3.524x | +748.16% |
| 2006-12-31 | $97.90 Million | $-53.23 Million | -0.544x | +97.65% |
| 2005-12-31 | $2.67 Million | $-61.74 Million | -23.167x | -1742.37% |
| 2004-12-31 | $-72.13 Million | $-101.75 Million | 1.411x | +199.25% |
| 2003-12-31 | $67.18 Million | $-95.47 Million | -1.421x | -134.12% |
| 2002-12-31 | $155.48 Million | $-94.38 Million | -0.607x | -2099.26% |
| 2001-12-31 | $223.10 Million | $-6.16 Million | -0.028x | +92.10% |
| 2000-12-31 | $66.37 Million | $-23.19 Million | -0.349x | +99.42% |
| 1999-12-31 | $800.00K | $-48.40 Million | -60.500x | -832.28% |
| 1998-12-31 | $-4.20 Million | $-34.70 Million | 8.262x | +1499.71% |
| 1997-12-31 | $34.90 Million | $-20.60 Million | -0.590x | -62.60% |
| 1996-12-31 | $58.40 Million | $-21.20 Million | -0.363x | -82.47% |
| 1995-12-31 | $75.90 Million | $-15.10 Million | -0.199x | +39.79% |
| 1994-12-31 | $46.00 Million | $-15.20 Million | -0.330x | -26.34% |
| 1993-12-31 | $58.50 Million | $-15.30 Million | -0.262x | +46.34% |
| 1992-12-31 | $39.80 Million | $-19.40 Million | -0.487x | -1820.50% |
| 1991-12-31 | $59.10 Million | $-1.50 Million | -0.025x | -- |
About Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of heredita… Read more